Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Biotechnology
The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease, under an agreement aimed at broadening access while linking payments to real-world treatment results. 16 July 2025
Related News
Insights
Company Spotlight
A Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and autoimmune/inflammatory diseases.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to prioritize high-value, high impact programs, meet its 2027 financial obligations, and support its long-term financial viability. 17 July 2025
Pharmaceutical
Swiss pharma giant Novartis this morning reported second quarter 2025 financial results, showing that net sales were $14.1 billion (+12%, +11% cc), with volume contributing 12 percentage points to growth. This was slightly better than the consensus estimate of $14.02 billion. 17 July 2025
Biotechnology
The Division of Hepatology and Nutrition of the US Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase IIa clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH), California, USA-based drug developer Kezar Life Sciences announced yesterday. 16 July 2025
Pharmaceutical
Alnylam has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. 16 July 2025
Biotechnology
US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical program showed that anselamimab, a light chain depleter antibody, did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis. 16 July 2025
Biotechnology
The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease, under an agreement aimed at broadening access while linking payments to real-world treatment results. 16 July 2025
Biosimilars
The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin aspart-xjhz, as a 3 mL single-patient-use prefilled pen and 10 mL multiple-dose vial. Kirsty is biosimilar to and interchangeable with Novolog (insulin aspart), from Denmark’s Novo Nordisk. 16 July 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ekterly (sebetralstat) 0for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. 15 July 2025
Biotechnology
USA-based Uniquity Bio has appointed industry veteran Will Kane as its president and chief executive. 15 July 2025
Pharmaceutical
San Diego, USA-based Neurocrine Biosciences on Monday reported new positive data from the Phase III CAHtalyst Adult study of Crenessity (crinecerfont) in adults with classic congenital adrenal hyperplasia (CAH), showing favorable trends in improvement of weight-related outcomes in CAH patients. 15 July 2025
Latest In Brief for Vertex Pharmaceuticals
Biosimilars
Hungarian drugmaker Gedeon Richter has announced that the European Commission has granted marketing authorization for the biosimilar denosumab products Junod and Yaxwer. 2 July 2025
Latest Relevant Ones To Watch News
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
16 May 2025
30 April 2025
28 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze